Prelude Therapeutics Incorporated
NMS: PRLDLive Quote
📈 ZcoreAI Score
Our AI model analyzes Prelude Therapeutics Incorporated's price action across multiple timeframes using regression channels and statistical scoring.
Get PRLD Z-Score →About Prelude Therapeutics Incorporated
Healthcare
Biotechnology
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
📊 Fundamental Analysis
Prelude Therapeutics Incorporated demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 41.0% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -99.5%, which indicates that capital utilization is currently under pressure.
At a current price of $4.08, PRLD currently trades near the top of its 52-week range (82%) (Range: $0.66 - $4.82).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$256.49M
Trailing P/E
--
Forward P/E
-3.56
Beta (5Y)
0.71
52W High
$4.82
52W Low
$0.66
Avg Volume
313K
Day High
Day Low